Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | SDCBP | O00560 | 4/20 | 0.58 |
| ▸ | SDC2 | P34741 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825642 | 0.88 | MAPT (1.00) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL4203635 | 0.88 | MAPT (1.00) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL20014176 | 0.81 | MAPT (0.85) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL18360806 | 0.80 | EGFR (0.63) | MAPTALOX15SMN1; SMN2LMNATHRB | |
| SCHEMBL825646 | 0.78 | MAPT (0.80) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL30506288 | 0.77 | ALOX15 (0.74) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL20116492 | 0.77 | ALOX15 (0.74) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL24064894 | 0.76 | ALOX15 (0.72) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL16266972 | 0.76 | ALOX15 (0.72) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL20014221 | 0.76 | ALOX15 (0.72) | MAPTALOX15SMN1; SMN2SDCBPSDC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3317273-B1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3317273-B1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-107849034-B | EGFR inhibitors and methods of use thereof | 达纳－法伯癌症研究所公司 | 2021-09-03 | — | — | CN | disclosed |
| US-20210094913-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20210094913-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-10836722-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836722-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10385019-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385019-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180290975-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2018-10-11 | — | — | US | disclosed |
| WO-2017004383-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094913-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | MAPT 3276/4885ALOX15 3841/4885SMN1; SMN2 4430/4885 |
| US-20180290975-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | MAPT 3276/4885ALOX15 3841/4885SMN1; SMN2 4430/4885 |
| US-10385019-B2 | Inhibitors of EGFR and methods of use thereof | EGFR, ERBB2, ERBB3 | MAPT 3276/4885ALOX15 3841/4885SMN1; SMN2 4430/4885 |
| US-10836722-B2 | Inhibitors of EGFR and methods of use thereof | EGFR, ERBB2, ERBB3 | MAPT 3276/4885ALOX15 3841/4885SMN1; SMN2 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.